Amgen Inc

$ 180.26 0.72 (0.4%)
Volume: 1,008,740 Avg Vol (1m): 2,702,108
Market Cap $: 110.16 Bil Enterprise Value $: 116.88 Bil
P/E (TTM): 14.41 P/B: 10.44
Earnings Power Value 118.18
Net Current Asset Value -28.78
Tangible Book -17.55
Projected FCF 202.16
Median P/S Value 175.88
Graham Number 0
Peter Lynch Value 177.68
DCF (FCF Based) 286.94
DCF (Earnings Based) 158.28
1Y (-%)

Financial Strength : 5.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.80
Cash-To-Debt range over the past 10 years
Min: 0.17, Med: 0.96, Max: 8.25
Current: 0.8
0.17
8.25
Equity-to-Asset 0.17
Equity-to-Asset range over the past 10 years
Min: 0.17, Med: 0.62, Max: 0.84
Current: 0.17
0.17
0.84
Debt-to-Equity 3.05
Debt-to-Equity range over the past 10 years
Min: 0.03, Med: 0.26, Max: 3.05
Current: 3.05
0.03
3.05
Debt-to-EBITDA 2.62
Debt-to-EBITDA range over the past 10 years
Min: 1.55, Med: 2.79, Max: 4.24
Current: 2.62
1.55
4.24
Interest Coverage 7.16
Interest Coverage range over the past 10 years
Min: 5.3, Med: 7.51, Max: 9.53
Current: 7.16
5.3
9.53
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.14
DISTRESS
GREY
SAFE
Beneish M-Score -2.63
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 47.26%
WACC 6.47%

Profitability & Growth : 9/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 42.14
Operating Margin range over the past 10 years
Min: 27.67, Med: 37.22, Max: 43.65
Current: 42.14
27.67
43.65
Net Margin % 34.00
Net Margin range over the past 10 years
Min: 8.66, Med: 28.98, Max: 35.35
Current: 34
8.66
35.35
ROE % 59.19
ROE range over the past 10 years
Min: 7.18, Med: 22.18, Max: 59.19
Current: 59.19
7.18
59.19
ROA % 12.00
ROA range over the past 10 years
Min: 2.51, Med: 9.16, Max: 12.11
Current: 12
2.51
12.11
ROC (Joel Greenblatt) % 193.14
ROC (Joel Greenblatt) range over the past 10 years
Min: 68.74, Med: 91.6, Max: 219.91
Current: 193.14
68.74
219.91
3-Year Total Revenue Growth Rate 3.10
3-Year Revenue Growth Rate range over the past 10 years
Min: 5.8, Med: 15.1, Max: 121.7
Current: 8.1
5.8
121.7
3-Year Total EBITDA Growth Rate 4.80
3-Year EBITDA Growth Rate range over the past 10 years
Min: 1.1, Med: 17.1, Max: 386.6
Current: 9.9
1.1
386.6
3-Year EPS w/o NRI Growth Rate 11.70
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 15.9, Max: 124.6
Current: 11.7
0
124.6

» AMGN's 30-Y Financials

Financials (Next Earnings Date: 2019-07-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:AMGN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325412    SIC : 2834
Compare XPAR:SAN NYSE:LLY NYSE:ABBV LSE:AZN LSE:GSK NAS:GILD NYSE:BMY NAS:CELG XTER:BAYA NAS:BIIB TSE:4519 TSE:4568 TSE:4503 XMAD:GRF.P TSE:4578 XSWX:NOVN SHSE:600436 HKSE:01093 TSE:4528 TSE:4151
Traded in other countries AMGN34.Brazil AMG.Germany 04332.Hongkong AMG N.Mexico 0R0T.UK
Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen Inc is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix and received approval for bone-strengthening drug Prolia/Xgeva.

Ratios

Current vs industry vs history
PE Ratio (TTM) 14.41
PE Ratio range over the past 10 years
Min: 10.4, Med: 15.87, Max: 76.27
Current: 14.41
10.4
76.27
Forward PE Ratio 13.09
N/A
PE Ratio without NRI 14.41
PE without NRI range over the past 10 years
Min: 10.4, Med: 15.87, Max: 76.27
Current: 14.41
10.4
76.27
Price-to-Owner-Earnings 12.32
Price-to-Owner-Earnings range over the past 10 years
Min: 9.72, Med: 12.85, Max: 22.43
Current: 12.32
9.72
22.43
PB Ratio 10.44
PB Ratio range over the past 10 years
Min: 1.8, Med: 3.85, Max: 11.29
Current: 10.44
1.8
11.29
PS Ratio 4.90
PS Ratio range over the past 10 years
Min: 3.09, Med: 4.77, Max: 6.55
Current: 4.9
3.09
6.55
Price-to-Free-Cash-Flow 11.98
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.85, Med: 12.51, Max: 20
Current: 11.98
8.85
20
Price-to-Operating-Cash-Flow 11.17
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 8.05, Med: 11.56, Max: 17.29
Current: 11.17
8.05
17.29
EV-to-EBIT 10.99
EV-to-EBIT range over the past 10 years
Min: 7.4, Med: 11.6, Max: 20.7
Current: 10.99
7.4
20.7
EV-to-EBITDA 9.28
EV-to-EBITDA range over the past 10 years
Min: 6.2, Med: 9.7, Max: 15.8
Current: 9.28
6.2
15.8
EV-to-Revenue 4.92
EV-to-Revenue range over the past 10 years
Min: 2.7, Med: 4.9, Max: 6.7
Current: 4.92
2.7
6.7
PEG Ratio 0.98
PEG Ratio range over the past 10 years
Min: 0.68, Med: 1.44, Max: 4.49
Current: 0.98
0.68
4.49
Shiller PE Ratio 24.42
Shiller PE Ratio range over the past 10 years
Min: 17.36, Med: 26.32, Max: 36.21
Current: 24.42
17.36
36.21
Current Ratio 2.77
Current Ratio range over the past 10 years
Min: 1.31, Med: 3.04, Max: 7.44
Current: 2.77
1.31
7.44
Quick Ratio 2.53
Quick Ratio range over the past 10 years
Min: 1.17, Med: 2.69, Max: 6.54
Current: 2.53
1.17
6.54
Days Inventory 259.76
Days Inventory range over the past 10 years
Min: 219.41, Med: 277.6, Max: 374.86
Current: 259.76
219.41
374.86
Days Sales Outstanding 57.95
Days Sales Outstanding range over the past 10 years
Min: 46.32, Med: 52.64, Max: 67.84
Current: 57.95
46.32
67.84
Days Payable 94.54
Days Payable range over the past 10 years
Min: 80.42, Med: 93.37, Max: 121.28
Current: 94.54
80.42
121.28

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 3.07
Trailing Dividend Yield range over the past 10 years
Min: 0.48, Med: 1.83, Max: 3.25
Current: 3.07
0.48
3.25
Dividend Payout Ratio 0.43
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.36, Max: 1.71
Current: 0.43
0.14
1.71
3-Year Dividend Growth Rate (Per Share) 18.70
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 63.3
Current: 18.7
0
63.3
Forward Dividend Yield % 3.23
N/A
Yield-on-Cost (5-Year) % 8.77
Yield-on-Cost (5y) range over the past 10 years
Min: 1.36, Med: 5.19, Max: 9.22
Current: 8.77
1.36
9.22
3-Year Share Buyback Rate 5.80
3-Year Share Buyback Rate range over the past 10 years
Min: -10.1, Med: 1.3, Max: 8.7
Current: 5.8
-10.1
8.7

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.90
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.61, Med: 1.75, Max: 9.49
Current: 0.9
0.61
9.49
Price-to-DCF (Earnings Based) 1.15
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.83, Med: 1.49, Max: 5.69
Current: 1.15
0.83
5.69
Price-to-Median-PS-Value 1.03
Price-to-Median-PS-Value range over the past 10 years
Min: 0.66, Med: 1.24, Max: 4.71
Current: 1.03
0.66
4.71
Price-to-Peter-Lynch-Fair-Value 1.02
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.58, Med: 1.4, Max: 4.12
Current: 1.02
0.58
4.12
Earnings Yield (Joel Greenblatt) % 9.09
Earnings Yield (Greenblatt) range over the past 10 years
Min: 4.8, Med: 8.6, Max: 13.6
Current: 9.09
4.8
13.6
Forward Rate of Return (Yacktman) % 21.40
Forward Rate of Return range over the past 10 years
Min: 11, Med: 19, Max: 26.5
Current: 21.4
11
26.5

More Statistics

Revenue (TTM) (Mil) $ 23,750
EPS (TTM) $ 12.53
Beta 0.95
Volatility % 21.63
52-Week Range $ 166.3 - 210.19
Shares Outstanding (Mil) 609.94

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y